Small Cell Lung Carcinoma, Stage IVA Lung Cancer AJCC v8, Stage IVB Lung Cancer AJCC v8, Stage IV Lung Cancer AJCC v8
Conditions
Brief summary
This phase II pilot trial studies how well gemcitabine and nivolumab work in treating participants with small cell lung cancer that has spread to other parts of the body after other treatments have failed. Drugs used in chemotherapy, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Monoclonal antibodies, such as nivolumab, may interfere with the ability of tumor cells to grow and spread. Giving second-line gemcitabine and nivolumab may work better in treating participants with small cell lung cancer.
Detailed description
PRIMARY OBJECTIVES: I. To compare response rate (RR) of gemcitabine and nivolumab (G+N) after 4 cycles (8 weeks) to historical controls treated with nivolumab alone. SECONDARY OBJECTIVES: I. To compare median overall survival (OS) of G+N to historical controls treated with nivolumab alone. II. To compare median progression-free survival (PFS) of G+N to historical controls treated with nivolumab alone. III. To evaluate for tolerability of G+N at each treatment cycle and then every 8 weeks after treatment is completed. EXPLORATORY OBJECTIVES: I. To correlate immunophenotypic changes among lymphocytes (quantitative measurements of CD4 and CD8 T-cells) with radiographic response and overall survival before treatment, after treatment and between 8-12 weeks after treatment. II. Among those patients with tumor mutation burden (TMB) status available, to describe the association between TMB (low, medium, or high) and RR, OS, and PFS. III. Assess the patient perspective of symptomatic adverse events using self-reported items from the National Cancer Institute (NCI) Patient Reported Outcomes-Common Terminology Criteria for Adverse Events (PRO-CTCAE). OUTLINE: Participants receive gemcitabine intravenously (IV) over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity. After completion of study treatment, participants are followed up at 30 days, 6-10 weeks, and every 8 weeks thereafter.
Interventions
DRUGGemcitabine
Given IV
BIOLOGICALNivolumab
Given IV
Sponsors
Wake Forest University Health Sciences
National Cancer Institute (NCI)
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients must have histologically or cytologically confirmed incurable SCLC and have had prior treatment with platinum-based chemotherapy. High-grade neuroendocrine tumors that are suspected to be of bronchopulmonary origin can be enrolled if they have had prior treatment with a SCLC chemotherapy regimen (e.g. platinum plus etoposide). * Patients should not be demonstrating end-organ damage due to rapid progression of disease based on the most recent assessment of the treating physician. * Patients must have radiographically measurable metastatic disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Absolute neutrophil count \>= 1,500/mcL. * Platelets \>= 100,000/mcL. * Chemotherapy agents are known to be teratogenic, therefore women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control) prior to study entry and for the duration of study participation. Should a woman become pregnant or suspect she is pregnant while participating in this study, she should inform her treating physician immediately. * Ability to understand and the willingness to sign an Institutional Review Board (IRB)-approved informed consent document.
Exclusion criteria
* Patients who have previously received either gemcitabine or an immune checkpoint inhibitor can be enrolled. * Emergent need for palliative radiation. * Patients may not be receiving any other investigational agents for the treatment of nonsmall cell lung cancer. * History of allergic reaction to gemcitabine. * Uncontrolled intercurrent illness including, but not limited to ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. * Pregnant women are excluded from this study because of the potential for teratogenic or abortifacient effects with chemotherapy. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with chemotherapy, breastfeeding should be discontinued.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants With Positive Responses to Therapy Per Response Evaluation Criteria in Solid Tumors (RECIST) | Up to 8 weeks | Objective RR (complete response \[CR\] + partial response \[PR\]) will be compared between this study sample and a historical benchmark value of 10%. For this comparison we will use a one-sample test of proportion. * Complete Response (CR): Disappearance of all target lesions. * Partial Response (PR): Decrease by ≥ 30% in sum of longest diameter of target lesions. * Stable Disease (SD): Not meeting criteria for CR, PR, or PD. * Progressive Disease (PD): Increase by ≥ 20% in sum of longest diameter of target lesions or the appearance of one or more new lesions. The response in non-target lesions is defined as follows: * Complete Response (CR): Complete disappearance of all non-target lesions. * Stable Disease (SD): Persistence of one or more non-target lesion(s). * Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Overall Survival (OS) - Number of Participants | Duration of time from the start of treatment to date of death, assessed up to 2 years | OS will be estimated using standard Kaplan Meier survival analysis methods. |
| Overall Survival (OS) - Months | Duration of time from the start of treatment to date of death, assessed up to 2 years | A median value (months) of overall survival will be estimated using standard Kaplan Meier survival analysis methods. |
| Progression-free Survival (PFS) - Number of Participants | Duration of time from the start of treatment to the time of investigator assessed progression or death, assessed up to 2 years | Progression-free survival will be estimated using standard Kaplan Meier survival analysis methods. Progression-Free Survival (PFS) is defined as the duration of time from the start of treatment to the time of investigator assessed progression or death. Progressive Disease (PD): Increase by ≥ 20% in sum of longest diameter of target lesions or the appearance of one or more new lesions |
| Progression-free Survival (PFS) - Months | Duration of time from the start of treatment to the time of investigator assessed progression or death, assessed up to 2 years | A median value (months) of progressive-free survival will be estimated using standard Kaplan Meier survival analysis methods. Progressive Disease (PD): Increase by ≥ 20% in sum of longest diameter of target lesions or the appearance of one or more new lesions |
| Number of Adverse Events | Up to 2 years | Toxicity rates will be estimated by responder status and presented overall and by body site per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORThomas W. Lycan
Wake Forest University Health Sciences
Participant flow
Participants by arm
| Arm | Count |
|---|---|
| Treatment (Gemcitabine, Nivolumab) Participants receive gemcitabine IV over 30 minutes and nivolumab IV over 60 minutes on day 1. Treatment repeats every 2 weeks for up to 4 courses in the absence of disease progression or unacceptable toxicity
Gemcitabine: Given IV
Nivolumab: Given IV | 14 |
| Total | 14 |
Baseline characteristics
| Characteristic | Treatment (Gemcitabine, Nivolumab) |
|---|---|
| Age, Continuous | 60.8 years STANDARD_DEVIATION 8.9 |
| Ethnicity (NIH/OMB) Hispanic or Latino | 0 Participants |
| Ethnicity (NIH/OMB) Not Hispanic or Latino | 14 Participants |
| Ethnicity (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) American Indian or Alaska Native | 0 Participants |
| Race (NIH/OMB) Asian | 0 Participants |
| Race (NIH/OMB) Black or African American | 2 Participants |
| Race (NIH/OMB) More than one race | 0 Participants |
| Race (NIH/OMB) Native Hawaiian or Other Pacific Islander | 0 Participants |
| Race (NIH/OMB) Unknown or Not Reported | 0 Participants |
| Race (NIH/OMB) White | 12 Participants |
| Region of Enrollment United States | 14 participants |
| Sex: Female, Male Female | 5 Participants |
| Sex: Female, Male Male | 9 Participants |
Adverse events
| Event type | EG000 affected / at risk |
|---|---|
| deaths Total, all-cause mortality | 8 / 14 |
| other Total, other adverse events | 11 / 14 |
| serious Total, serious adverse events | 1 / 14 |
Outcome results
Primary
Number of Participants With Positive Responses to Therapy Per Response Evaluation Criteria in Solid Tumors (RECIST)
Objective RR (complete response \[CR\] + partial response \[PR\]) will be compared between this study sample and a historical benchmark value of 10%. For this comparison we will use a one-sample test of proportion. * Complete Response (CR): Disappearance of all target lesions. * Partial Response (PR): Decrease by ≥ 30% in sum of longest diameter of target lesions. * Stable Disease (SD): Not meeting criteria for CR, PR, or PD. * Progressive Disease (PD): Increase by ≥ 20% in sum of longest diameter of target lesions or the appearance of one or more new lesions. The response in non-target lesions is defined as follows: * Complete Response (CR): Complete disappearance of all non-target lesions. * Stable Disease (SD): Persistence of one or more non-target lesion(s). * Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.
Time frame: Up to 8 weeks
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Gemcitabine, Nivolumab) | Number of Participants With Positive Responses to Therapy Per Response Evaluation Criteria in Solid Tumors (RECIST) | Partial response | 1 Participants |
| Treatment (Gemcitabine, Nivolumab) | Number of Participants With Positive Responses to Therapy Per Response Evaluation Criteria in Solid Tumors (RECIST) | Progressive disease | 11 Participants |
| Treatment (Gemcitabine, Nivolumab) | Number of Participants With Positive Responses to Therapy Per Response Evaluation Criteria in Solid Tumors (RECIST) | Lost to follow up | 2 Participants |
Secondary
Number of Adverse Events
Toxicity rates will be estimated by responder status and presented overall and by body site per Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
Time frame: Up to 2 years
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Treatment (Gemcitabine, Nivolumab) | Number of Adverse Events | 12 Number of adverse events reported |
Secondary
Overall Survival (OS) - Months
A median value (months) of overall survival will be estimated using standard Kaplan Meier survival analysis methods.
Time frame: Duration of time from the start of treatment to date of death, assessed up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Gemcitabine, Nivolumab) | Overall Survival (OS) - Months | 3.2 months |
Secondary
Overall Survival (OS) - Number of Participants
OS will be estimated using standard Kaplan Meier survival analysis methods.
Time frame: Duration of time from the start of treatment to date of death, assessed up to 2 years
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Gemcitabine, Nivolumab) | Overall Survival (OS) - Number of Participants | Deaths - any reason | 8 Participants |
| Treatment (Gemcitabine, Nivolumab) | Overall Survival (OS) - Number of Participants | Survivors | 6 Participants |
Secondary
Progression-free Survival (PFS) - Months
A median value (months) of progressive-free survival will be estimated using standard Kaplan Meier survival analysis methods. Progressive Disease (PD): Increase by ≥ 20% in sum of longest diameter of target lesions or the appearance of one or more new lesions
Time frame: Duration of time from the start of treatment to the time of investigator assessed progression or death, assessed up to 2 years
| Arm | Measure | Value (MEDIAN) |
|---|---|---|
| Treatment (Gemcitabine, Nivolumab) | Progression-free Survival (PFS) - Months | 1.8 months |
Secondary
Progression-free Survival (PFS) - Number of Participants
Progression-free survival will be estimated using standard Kaplan Meier survival analysis methods. Progression-Free Survival (PFS) is defined as the duration of time from the start of treatment to the time of investigator assessed progression or death. Progressive Disease (PD): Increase by ≥ 20% in sum of longest diameter of target lesions or the appearance of one or more new lesions
Time frame: Duration of time from the start of treatment to the time of investigator assessed progression or death, assessed up to 2 years
| Arm | Measure | Group | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|
| Treatment (Gemcitabine, Nivolumab) | Progression-free Survival (PFS) - Number of Participants | Participants that had disease progression | 11 Participants |
| Treatment (Gemcitabine, Nivolumab) | Progression-free Survival (PFS) - Number of Participants | Participants that did not have disease progression | 3 Participants |